The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global pharmaceutical continuous manufacturing market reached a value of US$ 1.05 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 2.24 Billion by 2027, exhibiting a CAGR of 12.70% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Pharmaceutical continuous manufacturing refers to an end-to-end medication production approach that enhances the quality and consistency of various novel drugs and vaccines with minimal capital investments. As compared to batch processing, it operates in a continuous flow, is easier to scale, offers greater control to manufacturers and a higher level of automation, and eliminates physical intervention. Apart from this, pharmaceutical continuous manufacturing aids in minimizing the medicine formulation duration, risk of human errors, monitoring the production procedures, and improving the product quality to harmonize with the regulatory guidelines. Consequently, the technique is extensively utilized by pharmaceutical companies and contract manufacturing organizations (CMOs) to develop active pharmaceutical ingredients (API) and medicines. At present, it is available in integrated, semi-continuous, and control types.
One of the primary factors currently driving the global pharmaceutical continuous manufacturing market is the increasing demand for effective medicine production systems for composing various effective biologics at a lower cost. This can be further attributed to the rising drug shortages and the growing prevalence of several chronic ailments across the globe. Additionally, the rising health concerns, especially during the coronavirus disease (COVID-19) pandemic outbreak, have prompted pharmaceutical companies to use continuous manufacturing techniques to compose novel vaccines, which is acting as another growth-inducing factor. In line with this, significant technological advancements, such as rapid automation in the pharmaceutical manufacturing methodology and the large-scale integration of artificial intelligence (AI) solutions, are contributing to the market growth. Other factors, such as significant improvements in the pharmaceutical sector, ongoing research and development (R&D) activities, and the escalating awareness about the availability of food and drug administration (FDA) approved medicines, are creating a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global pharmaceutical continuous manufacturing market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on therapeutics type, formulation, application and end user.
Breakup by Therapeutics Type:
Breakup by Formulation:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Baker Perkins, Coperion GmbH (Hillenbrand Inc.), Eli Lilly and Company, GEA Group Aktiengesellschaft, Glatt GmbH, Korsch AG, Novartis AG, Siemens, SK biotek, Thermo Fisher Scientific Inc. and Viatris Inc.
|Base Year of the Analysis||2021|
|Segment Coverage||Therapeutics Type, Formulation, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Baker Perkins, Coperion GmbH (Hillenbrand Inc.), Eli Lilly and Company, GEA Group Aktiengesellschaft, Glatt GmbH, Korsch AG, Novartis AG, Siemens, SK biotek, Thermo Fisher Scientific Inc. and Viatris Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at